The annual numbers lay bare the amplitude of the cycle.
After a 2022 peak of KRW 7,975.6bn in revenue and KRW 1,147.7bn in operating profit (a 14.4% margin), margins stayed sharply compressed: 2023 revenue of KRW 6,322.5bn with KRW 359.0bn operating profit (5.7%), 2024 revenue of KRW 7,155.0bn with KRW 272.8bn (3.8%), and 2025 revenue of KRW 6,915.1bn with KRW 271.8bn (3.9%).
Yet 2025 operating cash flow reached KRW 715.3bn, more than double the KRW 322.3bn of 2024, showing cash generation improving ahead of reported profit. Quarterly, operating profit fell from KRW 84.4bn in Q3 2025 to just KRW 1.6bn in Q4 2025, essentially break-even, and stayed at KRW 59.4bn in Q1 2026.
For the first quarter, the company said that despite early-year demand recovery and wider spreads, butadiene prices spiked in early March while downstream buyers stayed on the sidelines.
Q2 2026 then reversed to KRW 2,268.2bn in revenue, KRW 339.0bn in operating profit, and KRW 300.4bn in owners' net profit, with that single quarter's net profit exceeding full-year 2025 net profit of KRW 290.9bn.
Management said supply chain anxiety from the US-Iran clash spurred buyers to secure product, widening spreads on key items, that flexible output and sales adjustments plus minimal inventory aided profitability, and that higher glove maker utilization turned the NB Latex business profitable.
Summing the last four quarters (Q3 2025 through Q2 2026) gives roughly KRW 7,281.7bn in revenue and about KRW 484.4bn in operating profit, with Q2 2026 alone accounting for roughly 70% of that operating profit. The scale of improvement is clear, but so is the extreme concentration of that profit in a single period.
On the balance sheet, end-2025 equity of KRW 6,246.5bn against liabilities of KRW 2,227.9bn produced a debt-to-equity ratio of 35.7%, down from 38.0% in 2024.